Health and population

Health and population dynamics are intertwined, embodying an intricate relationship with significant implications on the Sustainable Development Goals (SDGs). Health is fundamentally at the center of these 17 global goals, aimed to transform the world by 2030. Specifically, Goal 3 endeavors to "Ensure healthy lives and promote well-being for all at all ages." It acknowledges that health is pivotal to human life quality, social cohesion, and sustainable development. Inextricably linked to this are the complexities of population dynamics, including growth rates, age structure, fertility and mortality rates, and migration patterns.

With the world's population projected to exceed 9.7 billion by 2050, the pressure on health systems will undoubtedly escalate. The demographic transition, with an aging population and an increasing prevalence of non-communicable diseases, poses new challenges for health systems globally. Additionally, areas with high fertility rates often overlap with extreme poverty, resulting in heightened health risks, including higher maternal and child mortality rates, malnutrition, and infectious diseases.

Moreover, rapid urbanization and migration present both opportunities and threats to health. While urban areas may provide better access to healthcare, they also harbor risks of disease transmission, air and water pollution, and social determinants of health like inadequate housing and social inequality. Simultaneously, migrants often face disproportionate health risks due to unstable living conditions, exploitation, and limited access to healthcare services.

Achieving the SDGs will necessitate comprehensive approaches that consider the intricate interplay of health and population dynamics. It means strengthening health systems, promoting universal health coverage, and addressing social determinants of health. It also implies crafting policies that recognize demographic realities and foster an environment conducive to sustainable development. Only by understanding and harnessing these dynamics can the world meaningfully progress towards realizing the SDGs, ensuring healthy lives and well-being for all.

This review highlights how nurse practitioners can strengthen Alzheimer’s disease care by supporting earlier diagnosis and access to treatment, which is essential for maintaining quality of life. Expanding their role helps reduce barriers in the healthcare system, ensuring people with Alzheimer’s receive timely care that promotes better health and well-being.
The article presents PI4AD, a computational medicine framework that integrates multi-omics data, systems biology, and artificial neural networks to prioritize therapeutic targets for Alzheimer's disease (AD). PI4AD recovers clinically validated targets like APP and ESR1, confirming its prioritization efficacy. The framework identifies Ras signaling as a central therapeutic hub, complementing traditional amyloid/tau-focused approaches. Crosstalk analysis reveals critical nodal genes (e.g., HRAS and MAPK1) and drug repurposing opportunities, bridging genetic insights with pathway-level biology.
The article discusses the potential of artificial intelligence (AI) in revolutionizing drug discovery for Alzheimer's disease (AD) and delirium. It explores how AI can facilitate target identification, small molecule and protein-based drug design, and optimization of pharmacokinetic properties to address the challenges in developing effective treatments for these two brain diseases.
The article suggest that beta-amyloid protein (Aβ) has a significant indirect effect on neurogranin (Ng) through key synaptic mediators such as SYT1 and GAP43 during the preclinical stages of Alzheimer’s disease (AD). These findings highlight the crucial role of SYT1 and GAP43 in mediating beta-amyloid-induced synaptic dysfunction, offering potential early biomarkers and therapeutic targets for AD progression.

The article provides a comprehensive consensus on optimal exercise recommendations for enhancing healthy longevity in older adults.�

This article investigates factors contributing to longer wait times in the Emergency Department for Non-Hispanic Black and Hispanic patients.

The article discusses the discovery of the A673V mutation in the amyloid precursor protein (APP) gene, which is associated with the familial form of Alzheimer's disease (AD) in a homozygous state. It provides an in-depth review of the molecular insights and therapeutic potential of the A?A2V peptide, including the development of a neuroprotective peptide A?1-6A2V(D) that inhibits amyloid-? aggregation and toxicity in preclinical models of AD and primary tauopathies

The article describes the development of a self-regulated multi-functional nano-modulator (siR/PIO@RP) that can intelligently navigate to the damaged blood-brain barrier and release therapeutic cargoes for synergetic Alzheimer's disease (AD) therapy. The nano-modulator is capable of reducing cerebral amyloid-β load, relieving neuroinflammation, and alleviating the dysfunction of the neurovascular unit, providing proof of concept that normalizing the neurovascular unit holds promise as a means of alleviating AD symptoms.
The article explores the associations between three healthy dietary patterns (DASH, aMED, and HDS) and homeostatic dysregulation (HD), a measure of aging-related physiological dysregulation, in a large prospective cohort from less-developed ethnic minority regions in China.
Elsevier,

Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Advances, 2025, pp 3-15

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by discussing the roles of Tau, glial, and amyloid (A) in Alzheimer's Disease development.

Pages